Azora Therapeutics, Inc. Common Stock
16 hedge funds and large institutions have $70.8K invested in Azora Therapeutics, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
14% more funds holding
Funds holding: 14 → 16 (+2)
8% less capital inflows, than outflows
Capital inflows: $37.4K | Capital outflows: $40.7K
2.57% less ownership
Funds ownership: 3.65% → 1.08% (-2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$15K |
| 2 |
HRT Financial
New York
|
+$11.5K |
| 3 |
Two Sigma Investments
New York
|
+$6.52K |
| 4 |
Citigroup
New York
|
+$2.4K |
| 5 |
Stone House Investment Management
Tunkhannock,
Pennsylvania
|
+$1.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$21.4K |
| 2 |
Virtu Financial
New York
|
-$17K |
| 3 |
1620 Investment Advisors
Plymouth,
Massachusetts
|
-$2.28K |
| 4 |
BPI
BFC Planning, Inc.
Cedar Rapids,
Iowa
|
-$18 |
AZR Hedge Fund Activity: Q2 2025 in Review
16 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Azora Therapeutics, Inc. Common Stock (AZR) for Q2 2025, worth a combined $70.8K — down 54% from $153K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AZR positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $15K. The largest seller was UBS Group, cutting an estimated $21.4K.
- 16 institutional investors held Azora Therapeutics, Inc. Common Stock (AZR) as of Q2 2025, up from 14 in Q1 2025.
- Funds reported $70.8K of Azora Therapeutics, Inc. Common Stock stock for Q2 2025, down 54% quarter-over-quarter.
- 5 funds opened new Azora Therapeutics, Inc. Common Stock positions in Q2 2025 and 3 closed out, a net change of +2 holders.
- The largest Azora Therapeutics, Inc. Common Stock buyer in Q2 2025 was Jane Street, an estimated $15K added.
- The largest Azora Therapeutics, Inc. Common Stock seller in Q2 2025 was UBS Group, an estimated $21.4K sold.
Based on aggregated 13F filings for Q2 2025.